How radical simplification can improve competitive agility in pharmaceuticals
Complexity—which is deeply rooted in pharmaceutical operating models in the US and worldwide—has become a silent killer of operational excellence, innovation, profitability and ultimately, competitive agility in the industry. Nearly half of the largest global pharmaceutical companies have reached complexity levels not in line with current profitability.
Simple and agile pharmaceutical companies in the United States will have the advantage in today’s world where healthcare segments are converging and new technology is reinventing business models. Shifting to the new—such as expanding into the realm of patient services, diagnostics and provider collaborations—should happen in parallel with simplification.READ THE REPORT [PDF]